Market Closed -
Nasdaq
04:30:00 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
4.615
USD
|
-3.25%
|
|
+0.98%
|
-17.88%
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
105.5
|
91.77
|
143.7
|
103.9
|
66.71
|
62.74
|
-
|
-
|
Enterprise Value (EV)
1 |
105.5
|
91.77
|
143.7
|
103.9
|
66.71
|
62.74
|
62.74
|
62.74
|
P/E ratio
|
908
x
|
-45.4
x
|
537
x
|
192
x
|
-12.6
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.9
x
|
2.86
x
|
3.5
x
|
2.11
x
|
1.24
x
|
1.28
x
|
1.17
x
|
1.06
x
|
EV / Revenue
|
3.9
x
|
2.86
x
|
3.5
x
|
2.11
x
|
1.24
x
|
1.28
x
|
1.17
x
|
1.06
x
|
EV / EBITDA
|
120
x
|
-90
x
|
94.4
x
|
47
x
|
-30.9
x
|
-9.56
x
|
-23.7
x
|
-
|
EV / FCF
|
103
x
|
134
x
|
-29
x
|
-
|
61.6
x
|
-7.91
x
|
-8.94
x
|
-21.9
x
|
FCF Yield
|
0.97%
|
0.75%
|
-3.45%
|
-
|
1.62%
|
-12.6%
|
-11.2%
|
-4.56%
|
Price to Book
|
57.1
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,615
|
11,888
|
13,390
|
13,522
|
13,559
|
13,594
|
-
|
-
|
Reference price
2 |
9.080
|
7.720
|
10.73
|
7.680
|
4.920
|
4.615
|
4.615
|
4.615
|
Announcement Date
|
7/15/19
|
7/27/20
|
7/22/21
|
7/21/22
|
7/24/23
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
27.07
|
32.12
|
41.04
|
49.11
|
53.87
|
48.84
|
53.68
|
59.31
|
EBITDA
1 |
0.876
|
-1.02
|
1.522
|
2.21
|
-2.157
|
-6.559
|
-2.645
|
-
|
EBIT
1 |
0.27
|
-1.803
|
0.338
|
0.607
|
-5.256
|
-9.502
|
-5.674
|
-1.483
|
Operating Margin
|
1%
|
-5.61%
|
0.82%
|
1.24%
|
-9.76%
|
-19.45%
|
-10.57%
|
-2.5%
|
Earnings before Tax (EBT)
1 |
0.231
|
-1.845
|
0.409
|
0.583
|
-5.267
|
-9.53
|
-5.654
|
-
|
Net income
|
0.128
|
-1.975
|
0.334
|
0.548
|
-5.335
|
-
|
-
|
-
|
Net margin
|
0.47%
|
-6.15%
|
0.81%
|
1.12%
|
-9.9%
|
-
|
-
|
-
|
EPS
|
0.0100
|
-0.1700
|
0.0200
|
0.0400
|
-0.3900
|
-
|
-
|
-
|
Free Cash Flow
1 |
1.028
|
0.685
|
-4.962
|
-
|
1.083
|
-7.93
|
-7.015
|
-2.86
|
FCF margin
|
3.8%
|
2.13%
|
-12.09%
|
-
|
2.01%
|
-16.24%
|
-13.07%
|
-4.82%
|
FCF Conversion (EBITDA)
|
117.35%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
803.12%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/15/19
|
7/27/20
|
7/22/21
|
7/21/22
|
7/24/23
|
-
|
-
|
-
|
Fiscal Period: April |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
11.79
|
13.19
|
12.88
|
13.74
|
14.28
|
12.77
|
13.07
|
12.56
|
11.57
|
12.02
|
12.69
|
13.1
|
13.32
|
13.53
|
13.72
|
EBITDA
1 |
0.635
|
1.194
|
0.222
|
0.226
|
0.686
|
-1.516
|
-1.749
|
-1.67
|
-1.418
|
-1.659
|
-1.707
|
-0.816
|
-0.775
|
-0.422
|
-0.632
|
EBIT
1 |
0.263
|
0.83
|
-0.311
|
-0.284
|
0.007
|
-2.458
|
-2.521
|
-2.552
|
-1.955
|
-2.577
|
-2.418
|
-1.567
|
-1.476
|
-1.273
|
-1.358
|
Operating Margin
|
2.23%
|
6.29%
|
-2.42%
|
-2.07%
|
0.05%
|
-19.24%
|
-19.29%
|
-20.32%
|
-16.89%
|
-21.44%
|
-19.05%
|
-11.96%
|
-11.08%
|
-9.41%
|
-9.9%
|
Earnings before Tax (EBT)
1 |
0.289
|
0.798
|
-0.346
|
-0.302
|
-0.002
|
-2.422
|
-2.541
|
-2.538
|
-2.06
|
-2.519
|
-2.413
|
-1.562
|
-1.471
|
-1.268
|
-1.353
|
Net income
|
0.277
|
0.787
|
-0.344
|
-0.319
|
-0.016
|
-2.439
|
-2.561
|
-2.566
|
-2.071
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
2.35%
|
5.97%
|
-2.67%
|
-2.32%
|
-0.11%
|
-19.09%
|
-19.59%
|
-20.43%
|
-17.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.0200
|
0.0500
|
-0.0200
|
-0.0200
|
-
|
-0.1800
|
-0.1900
|
-0.1900
|
-0.1500
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/13/21
|
3/15/22
|
7/21/22
|
9/12/22
|
12/13/22
|
3/15/23
|
7/24/23
|
9/13/23
|
12/12/23
|
3/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1.03
|
0.69
|
-4.96
|
-
|
1.08
|
-7.93
|
-7.02
|
-2.86
|
ROE (net income / shareholders' equity)
|
11.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
1.32%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
9.697
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.1600
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
0.1300
|
0.2500
|
-0.1300
|
0.2200
|
-0.1600
|
-
|
-
|
-
|
Capex
1 |
0.83
|
2.22
|
3.28
|
2.38
|
2.87
|
1.07
|
2.6
|
2.67
|
Capex / Sales
|
3.08%
|
6.91%
|
7.99%
|
4.85%
|
5.33%
|
2.2%
|
4.84%
|
4.49%
|
Announcement Date
|
7/15/19
|
7/27/20
|
7/22/21
|
7/21/22
|
7/24/23
|
-
|
-
|
-
|
Last Close Price
4.615
USD Average target price
6
USD Spread / Average Target +30.01% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.88% | 62.74M | | +46.19% | 55.7B | | -6.14% | 39.57B | | +39.19% | 39.91B | | -6.65% | 28.16B | | +12.33% | 26.3B | | -21.78% | 18.94B | | -0.35% | 12.12B | | +24.18% | 12.12B | | +28.38% | 12.17B |
Other Biotechnology & Medical Research
|